Ahmet Çamsarı

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Slow coronary flow may be a sign o diffuse atherosclerosis

Haşan Pekdemir, Dilek Çiçek, Ahmet Çamsarı et al. · Acta Cardiologica · 2004 · 126 citations

Medicine, Cardiology, Clinical Sciences +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Increased Levels of High Sensitive C-Reactive Protein in Patients with Chronic Rheumatic Valve Disease: Evidence of Ongoing Inflammation

Zehra Gölbaşı, Özgül Uçar, Telat Keleş et al. · European Journal of Heart Failure · 2002 · 100 citations · Full text

Veterinary Medicine, Cardiology, Immunology +13